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Abstract
Background:  The  rare  incidence  of  primary  malignant  melanoma  of  the  central  nervous  system
and its  ability  to  mimic  other  melanocytic  tumours  on  images  make  it  a  diagnostic  challenge
for the  neurosurgeon.
Clinical  case: A  51-year-old  patient,  with  a  tumour  located  in  the  right  forniceal  callosum  area.
Total surgical  excision  was  performed.  Histopathological  result  was  consistent  with  the  diagnosis
of primary  malignant  melanoma  of  the  central  nervous  system,  after  ruling  out  extracranial  and
extraspinal  melanocytic  lesions.
Conclusions:  The  primary  malignant  melanoma  of  the  central  nervous  system  is  extremely  rare.
There are  features  in  magnetic  resonance  imaging  that  increase  the  diagnostic  suspicion;  never-
theless there  are  other  tumours  with  more  prevalence  that  share  some  of  these  features  through
image. Since  there  is  not  an  established  therapeutic  standard  its  prognosis  is  discouraging.
© 2015  Academia  Mexicana  de  Cirugía  A.C.  Published  by  Masson  Doyma  México  S.A.  This
is an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).PALABRAS  CLAVE Melanoma  maligno  primario  del  sistema  nervioso  central:  un  reto  diagnóstico
Melanoma  maligno
primario;
Sistema  nervioso
central;
Resumen
Antecedentes:  La  rara  incidencia  del  melanoma  maligno  primario  del  sistema  nervioso  central
y su  capacidad  de  mimetizar  por  imagen  otros  tumores  melanocíticos  lo  hacen  ser  un  reto
diagnóstico  para  el  neurocirujano.
 Please cite this article as: Quillo-Olvera J, Uribe-Olalde JS, Alcántara-Gómez LA, Rejón-Pérez JD, Palomera-Gómez HG. Melanoma
maligno primario del sistema nervioso central: un reto diagnóstico. Cir Cir. 2015; 83: 129--134.
∗ Corresponding author at: Doctores 102 Col. El Marqués, 76047 Querétaro, Querétaro, México. Tel.: +52 01 44 2223 6904.
E-mail address: a i o n@hotmail.com (J. Quillo-Olvera).
2444-0507/© 2015 Academia Mexicana de Cirugía A.C. Published by Masson Doyma México S.A. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Caso  clínico:  Presentamos  el  caso  de  una  paciente  femenina  de  51  an˜os  de  edad,  con  un
tumor localizado  en  el  área  calloso  forniceal  derecha.  Se  realizó  exéresis  quirúrgica  total,
y el  resultado  histopatológico  fue  compatible  con  el  diagnóstico  de  melanoma  maligno  primario
del sistema  nervioso  central,  habiéndose  descartado  lesiones  extracraneales  y  extrarraquídeas
mucotegumentarias  melanocíticas.
Conclusiones:  El  melanoma  maligno  primario  del  sistema  nervioso  central  es  extremadamente
raro. Existen  características  en  imagen  de  resonancia  magnética  que  incrementan  la  sospecha
diagnóstica.  Sin  embargo,  hay  otros  tumores  más  prevalentes  que  comparten  algunas  de  esas
características  por  imagen.  No  hay  un  estándar  terapéutico  establecido.  Su  pronóstico  es
desalentador.
© 2015  Academia  Mexicana  de  Cirugía  A.C.  Publicado  por  Masson  Doyma  México  S.A.  Este
es un  artículo  Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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rimary  melanocytic  tumours  of  the  central  nervous  system
re  rare,  histologically  and  clinically  different  from  metas-
ases  from  retinal  or  cutaneous  malignant  melanoma.1 They
re  classiﬁed  into  diffuse  melanocytosis  (diffuse  melanosis)
nd  meningeal  melanomatosis,  malignant  melanoma  and
enign  melanocytoma,  with  a  small  number  of  intermedi-
te  variants.1 This  set  of  primary  melanocytic  neoplasms  of
he  central  nervous  system  have  an  extraordinary  incidence,
stimated  at  0.9  per  10  million  inhabitants.2 Of  these,  pri-
ary  malignant  melanoma  of  the  central  nervous  system
s  even  more  unusual:  it  accounts  for  1%  of  all  cases  of
elanoma3,4 and  0.7%  of  all  primary  tumours  of  the  central
ervous  system.5 Its  incidence  is  speciﬁcally  0.005  cases  per
00,000  individuals.6 It  presents  in  an  age  range  from  35
o  50.7 Bhandari  et  al.2 state  that  it  was  Virchow  who,  in
859,  described  the  ﬁrst  case  of  primary  diffuse  intracra-
ial  melanoma,  and  Oogle  reported  in  1899  the  ﬁrst  case
f  primary  solitary  intracranial  melanoma.7,8 These  tumours
rise  from  melanocytes  present  in  the  leptomeninges  in  the
erebral  convexity,  in  the  skull  base,  posterior  fossa,  cer-
ical  spinal  canal,  the  pia  mater  covering  vessels,  reticular
ormation  of  the  bridge  and  spinal  cord,  black  substance  and
ocus  coeruleus.7 The  most  common  sites  within  the  central
ervous  system  are:  lobar  (53.1%),  posterior  fossa  (17.3%)
nd  pineal  region  (13.6%).2 The  diagnosis  of  these  tumours
s  difﬁcult;  it  has  to  be  carried  out  by  exclusion,  with
rimary  melanocytic  tumours  of  the  central  nervous  system,
rimary  tumours  of  the  central  nervous  system  with  a  cer-
ain  degree  of  melanisation,  and  mainly  with  metastases
rom  primary  extracranial  melanoma,  the  most  common
eoplasm  causing  cerebral  metastases  after  lung  cancer  and
reast  cancer.8,9 Although  the  prognosis  of  patients  with
rimary  malignant  melanoma  of  the  central  nervous  sys-
em  is  discouraging,  especially  in  cases  with  leptomeningeal
issemination,6,10 and  this  being  the  most  direct  progno-
is  factor,11 it  seems  highly  dependent  on  a  full  tumour
10,12esection.
A  current  review  of  PubMed  literature  on  primary  malig-
ant  melanoma  of  the  central  nervous  system  was  carried
ut.  Due  to  its  low  incidence,  report  cases  and  small  series  of
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iases  were  found.  Also,  it  must  be  considered  that  in  Mexico
here  is  only  one  case  of  primary  malignant  melanoma  of  the
entral  nervous  system,  reported  in  2008  by  Avilés-Aguilar
t  al.,13 conﬁrming  the  rare  incidence  of  this  tumour.  In  this
rticle  we  document  and  present  the  radiological  character-
stics,  macroscopic,  histological  and  immunohistochemistry
ndings,  and  discuss  the  potential  aetiological  genotype,
urrent  management  options  and  the  prognosis  of  this  infre-
uent  entity.  An  illustrative  case  treated  in  our  neurosurgery
ervice  is  presented.
linical case
his  clinical  case  is  of  a  female  patient,  51  years  of  age,
ith  no  relevant  history  for  her  current  condition.  The
ymptoms  described  upon  admission  had  one  month  of  pro-
ression,  with  holocranial  headache,  mostly  in  the  morning.
pon  admission  the  patient  mentioned  intense  holocra-
ial  headache,  which  ceased  momentaneously  with  NSAID
nd  was  worsened  with  the  Valsalva  manoeuvre.  She  had
ifﬁculty  in  moving  her  left  arm  and  leg,  leading  to  ambu-
atory  problems.  In  the  physical  examination  we  found:
roper  alertness,  bradifrenia,  3/5  strength  decrease  in
eft  arm  and  leg,  and  generalised  hypertonia  and  hyper-
eﬂexia  in  the  four  limbs.  Bilateral  papillary  oedema  was
bserved  in  the  ophthalmoscopy.  The  simple  cranium  axial
omography,  carried  out  upon  admission  (Fig.  1),  showed
 hyperdense,  well-deﬁned  image,  right  temporoparietal,
pparently  intraventricular,  with  collapse  of  the  right  lat-
ral  ventricle,  mainly  the  atrium,  and  severe  expansive
ffect.  The  lesion  presented  heterogeneous  areas  of  den-
ity.  It  extends  up  to  the  right  parietal  lobe.  Its  medial
imits  are  the  right  fornix  callosum  region,  extending  along
he  occipital  horn.  Compression  of  the  callosum  body  is  evi-
ent,  as  well  as  the  fornix  cross-sectional  area  on  the  right
ide.  The  left  ventricular  system  is  perceived  as  perme-
ble,  with  no  compensatory  dilation.  A  magnetic  resonance
maging  study  was  also  performed.  In  the  axial  T1  weighted
mage  (Fig.  2),  the  craneodorsal  extension  of  the  tumour
as  observed;  the  tumour  was  intraaxial  and  isointense
n  relation  to  the  cerebral  parenchyma,  and  intratumoural
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hyperintense  areas,  with  suspected  intratumoural  micro-
haemorrages.  The  expansive  effect  over  the  body  of  the
fornix,  the  fornix  cross-sectional  area,  the  bulb  of  the  cor-
pus  callosum  and  the  splenium  of  the  corpus  callosum  on  the
right  side  was  evident,  in  addition  to  the  complete  collapse
of  the  body  and  atrium  of  the  right  ventricular  system  and
apparent  occupation  of  the  ipsilateral  occipital  horn.  In  the
T1  weighted  image  with  contrast  material,  the  same  hyper-
intense  lesion  was  observed,  homogeneously  enhanced  by
the  gadolinium.  In  the  axial  T2  weighted  image  (Fig.  3)  a
hypointense  lesion  was  observed.
Figure  2  Simple  axial  T1  magnetic  resonance  image.
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Tigure  3  Hypointense  lesion  in  axial  T2  magnetic  resonance.
In  her  ﬁrst  hospital  stay,  a  loop  diuretic  was  administered,
teroid,  anticonvulsant  and  semi-Fowler’s  position.  Also,  an
lective  surgical  treatment  was  proposed.  The  presump-
ive  diagnosis  was  meningioma,  and  a  differential  diagnosis
as  performed  in  the  location  between  choroid  plexus
apilloma,  metastases  and  glioma  for  ventricular  atrium
umours,  without  taking  into  consideration  primary  malig-
ant  melanoma  of  the  central  nervous  system.  On  the  fourth
ay  she  presented  sudden  deterioration  of  alertness  and
onsciousness,  dilated  right  pupil  and  2/5  tetraparesis,  with
ccentuation  of  the  superior  motor  neuron  syndrome  she
ad  upon  admission,  and  clinical  signs  of  right  uncal  herni-
tion  were  added.  Therefore,  an  emergency  decompressive
ight  temporal  craniectomy  was  performed.  Pressure  was
eleased  on  the  craniotomised  temporal  fossa.  She  was
dmitted  into  the  intensive  care  unit  in  the  postsurgical
tage.
Afterwards,  in  better  clinical  condition  and  having
mproved  the  right  pupillary  diameter,  on  her  ﬁrst  day  in
he  intensive  care  unit,  she  went  into  surgery  for  a  tumoral
esection.  A  posterosuperior  craniotomy  was  performed,  as
ell  as  a  superior  intersulcal,  right  parietal  approach.  There
as  total  resection  of  the  tumour.  The  macroscopic  char-
cteristics  of  the  tumour  were  soft  neoplastic,  aspirable,
ighly  vascularised  and  bleeding,  with  vessel  clusters,  of  low
uality  and  difﬁcult  coagulation,  parenquimatose  and  lep-
omeningeal  inﬁltration.  During  surgery,  an  intraaxial  lobar
nd  extraventricular  tumour  was  conﬁrmed,  with  severe
xpansive  effect  on  the  right  lateral  ventricular  system.  The
ain  characteristic  of  this  tumour  is  that  it  was  ‘‘black’’  in
olour  (Fig.  4).
Two  weeks  after  the  surgery,  a  simple  tomography  of
he  head  was  taken,  where  midbrain  was  observed  with  no
vidence  of  compression,  an  area  of  right  temporoparietal
ncefalomalacia,  secondary  to  the  total  tumour  resection.
he  right  lateral  ventricular  system  with  no  collapse,
132  J.  Quillo-Olvera  et  al.
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Figure  5  Nests  of  epithelioid  cells,  with  cytoplasmic  melanin,
pleomorphic  nuclei  and  prominent  nucleoli,  with  atypical
mitotic  ﬁgures.
F
m
digure  4  ‘‘Black’’  colour  tumour,  through  transcortical
ccess,  highly  vascularised,  intraaxial.
ermeable  right  occipital  horn  and  atrium,  with  no
ransependimary  communication,  because  the  tumour  was
xtraventricular  and  those  structures  were  not  injured  dur-
ng  resection.  The  review  of  the  histopathology  sample
evealed  a  highly  cellular  neoplasia,  organised  in  nests  of
pithelial  cells,  with  pleomorphic  nuclei  and  a  variable
mount  of  cytoplasmic  melanin,  in  addition  to  prominent
ucleoli  (Figs.  5  and  6),  and  positive  for  HMB45  and  S-
00  protein.  With  the  postsurgical  ﬁndings  mentioned  and
he  previous  immunohistochemistry,  a  directed  anamne-
is  was  performed,  regarding  the  family  history  of  skin
eoplasms  in  the  patient,  which  were  denied.  The  case
as  formalised  by  the  dermatology  and  ophthalmology
ervice,  and  an  exhaustive  review  was  carried  out  to  exclude
ucotegumentary  lesions  and  primary  retinal  neoplastic
esions.
Having  ruled  out  metastatic  tumours  of  the  central  ner-
ous  system  with  the  use  of  negative  tumour  markers  and
cintigram,  the  ﬁnal  conclusion  was  a  diagnosis  of  primary
alignant  melanoma  of  the  central  nervous  system.  The
atient  was  discharged  9  days  after  her  postsurgical  status,
he  oncology  service  determined  total  cerebral  radiothe-
apy  with  3.000  centigray  in  10  fractions,  concomitant  with
emozolamide  for  6  weeks.  She  is  currently  under  oncology
reatment.
iscussion
elanosomic  melanin  is  different  from  neuromelanin,  which
s  only  found  on  neurons.9 Leptomeningeal  melanocytes  are
erived  from  the  neural  crest,  consisting  of  a  population  of
ultipotential  cells  arising  from  the  lateral  margin  of  the
eural  tube  during  early  embryo  development,  on  day  22  of
he  embryogenesis,  differentiating  in  leptomeningeal  cells,
lial  cells,  medullar  adrenal  cells  and  melanocytes.12 The
igher  concentration  of  melanocytes  in  the  nervous  system  is
n  the  pia  mater,  around  the  spinal  cord  and  the  high  cervical
ord.2,14 However,  it  is  possible  for  the  primary  melanoma  to
rise  from  heterotopic  masses  of  melanocytes  in  the  central
ervous  system.2
t
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nigure  6  Epithelioid  cell  islands  are  observed,  with  high
elanin  content.
Several  theories  have  been  proposed,  such  as:  (1)  Meso-
ermal  theory,  stating  that  the  cell  pigment  arises  from
he  mesoderm  and  reaches  the  brain  or  spine  through  pial
lood  vessels.  (2)  Ectodermal  theory,  where  only  epithelial
ells  can  produce  pigment;  therefore,  the  primary  malig-
ant  melanoma  of  the  central  nervous  system  derive  from
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aberrant  embrionary  ectodermal  cells.  (3)  Neurogenic  the-
ory:  pigmented  cells  are  derived  from  the  neural  crest  and
may  cause  tumours.3 Chromosome  abnormalities  have  also
been  reported,  such  as  the  deletion  or  rupture  in  the  long
and  short  arm  of  chromosome  6,  with  a  potential  loss  in  the
function  of  tumour  suppressor  genes  in  primary  malignant
melanoma  of  the  central  nervous  system,15 and  experimen-
tal  models  have  been  designed  on  mice  showing  the  role
of  oncogenes16,17 and  the  appearance  of  primary  malig-
nant  melanoma  of  the  central  nervous  system  on  mice
when  the  oncogene  NRAS  is  expressed  in  melanocytes  dur-
ing  embryogenesis  through  an  endogenous  NRAS  promoter.18
It  is  known  that  this  oncogene  induces  proliferation  of
melanocytes  and  congenital  melanocytic  lesions  in  humans.
The  acquisition  of  somatic  mutations  in  the  NRAS  oncogene
in  melanocytes  of  the  central  nervous  system  is  a  risk  factor
predisposing  to  primary  melanoma  of  the  central  nervous
system  in  children.16 Other  somatic  mutations,  such  as  that
of  the  GNAQ  gen,  at  codon  209,  are  frequent  events  in
primary  melanocytic  neoplasms  of  the  central  nervous  sys-
tem,  with  relevance  in  the  future  immunotherapy  of  these
tumours.17 Histopathology  ﬁndings  commonly  found  in  the
primary  malignant  melanoma  of  the  central  nervous  system
consist  of  pigmented  tumour  cells,  cytologically  atypical,
with  invasion  to  the  central  nervous  system,  pleomorphic
nuclei;  these  are  highly  cellular  neoplasms,  organised  in
a  syncytial  pattern,  epithelial,  or  irregular  conglomerates
of  pigmented  cells  with  leptomeningeal  inﬁltration.12 How-
ever,  a  discouraging  prognosis  has  been  observed  when  these
lesions  are  large,  indurated,  with  deep  invasion,  epithelioid
cellular  pattern  and  marked  mitotic  activity.10,19
The  peak  of  incidence  of  primary  malignant  melanoma
of  the  central  nervous  system  is  in  the  fourth  and  ﬁfth
decade  of  life,  and  has  a  preponderance  in  males.2,4
Presentation  symptoms  include  intracranial  hypertension
and  hydrocephalus  (43.2%),  focal  neurologic  deﬁcit  due
to  cerebral  and  spinal  compression  effect  (34.6%),  sub-
arachnoid  haemorrhage  (17.3%)  and  convulsions  (11.1%).  It
may  be  found  as  solitary  or  in  the  context  of  neurocuta-
neous  melanosis,12,20 and  associations  have  been  described
between  primary  malignant  melanoma  and  giant  congeni-
tal  nevo,  although  it  is  rare,21 and  transoperatory  ﬁndings
between  leptomeningeal  melanosis  and  primary  melanoma
of  the  central  nervous  system.22 The  beginning  of  symptoms
may  be  acute,  potentially  associated  to  intratumoural  haem-
orrhages,  common  in  this  tumour.15 70%  of  these  lesions  are
black  as  surgical  ﬁnding.12
Typical  radiologic  characteristics  in  cranial  computed
tomography  are  those  of  a  hyperdense  lesion,  in  images
with  no  contrast  material.2 In  the  magnetic  resonance  we
observe  a  hyperintense  tumour  in  T1  and  hypointense  in
T2.2 This  is  due  to  the  paramagnetic  effect  of  stable  free
radicals  of  melanin.2,23 Odd  electrons  of  melanin  and  pro-
tons  of  water  produce  a  dipole-dipole  interaction  causing
hyperintensity  in  T1  and  hypointensity  in  T2.9 However,
there  are  variants  in  relation  to  these  ﬁndings:  hypointen-
sity  in  T1  and  hyperintensity  in  T2,  predominantly  found  in
tumours  with  less  than  10%  of  melanin  in  its  cells,23 and
in  tumours  with  intralesional  haemorrhage.4 The  only  imag-
ing  sign  for  diagnosis  is  leptomeningeal  dissemination.2
Other  primary  tumours  must  be  taken  into  consideration
in  the  differential  diagnosis  with  the  primary  malignant
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elanoma  of  the  central  nervous  system,  such  as  menin-
ioma,  meduloblastoma,  astrocytoma,  melanotic  schwan-
oma,  pituitary  tumours,  choroid  plexum  papillomas.2
There  is  much  controversy  if  upon  diagnosis  of  a
elanoma  this  is  primary  of  the  central  nervous  system
r  metastatic;  however,  Hayward24 proposed  in  1976  the
ollowing  classiﬁcations:  (1)  Primary  malignant  melanoma
f  the  central  nervous  system.  (2)  Secondary  malignant
elanoma  of  the  central  nervous  system.  (3)  Variants  of
ther  intracranial  tumours  with  melanin.  For  the  purposes
f  classifying  these  tumours,  the  factors  to  look  for  are
s  follows:  (a)  with  no  ﬁnding  of  malignant  melanoma
utside  the  central  nervous  system;  (b)  cranial  or  spinal  lep-
omeninges  taken  by  the  tumour;  (c)  intramedullary  spinal
esions;  (d)  hydrocephalus;  (e)  tumour  in  the  pineal  or  pitu-
tary  gland,  and  (f)  solitary  cerebral  lesion.24 These  criteria
re  still  relevant  and  used  currently,  because  the  immuno-
istochemical  diagnosis  or  differential  histological  diagnosis
etween  the  primary  and  secondary  malignant  melanoma  of
he  central  nervous  system  is  difﬁcult.25
The  ﬁnal  diagnosis  has  to  be  performed  by  a  pathologist,
aking  into  consideration  the  result  of  immunohistochem-
cal  markers  used,  such  as  the  S100  protein  (expressed
n  cells  originated  in  the  neural  crest),  HMB45  (detected  in
elanosomas)  and  Melan.2 Generally  this  tumour  is  nega-
ive  for  glial  ﬁbrillary  acidic  protein  (GFAP)  and  epithelial
embrane  antigen  (EMA).26
Surgical  treatment  is  the  main  option.2 The  use  of  com-
ined  chemotherapy,  such  as  decarbazine  together  with  1-
4-amino-2-methyl-5-pyrimidinyl)  methyl-3-(2-chloroethyl)
-nitrosourea  hydrochloride  (ACNU)  and  vincristine  with  OK
32  (picibanil),  has  proven  promising  results  in  neoplasms
f  metastatic  and  primary  origin.2 In  2011  the  FDA  approved
ew  medication  for  malignant  metastatic  melanoma  of  the
entral  nervous  system;  a new  immunotherapy  with  ipil-
mumab  and  vemurafenib,  blocker  of  mitogen-activated
rotein  (MAP)  kinase,27 which  may  be  used  in  cerebral
rimary  malignant  melanoma;  however,  there  are  still  no
linical  trials  or  clinical  evidence  to  support  its  use  as  a
ole  therapy.  Most  authors  agree  that  there  is  no  deﬁned
herapy  standard,  and  the  efﬁcacy  of  radiotherapy  and
hemotherapy  on  cerebral  primary  malignant  melanoma
s  still  controversial.28 The  prognosis  of  cerebral  primary
alignant  melanoma  is  better  than  that  of  metastatic  malig-
ant  melanoma,  especially  with  full  resection,12 since,
espite  the  aggressive  multimodal  management,  in  cerebral
econdary  malignant  melanoma  a  survival  of  3--6  months  is
eported,15 compared  to  that  of  patients  with  diagnosis  of
olitary  primary  malignant  melanoma  of  the  central  nervous
ystem,  which  is  20.7  months.11
onclusion
he  diagnosis  of  primary  malignant  melanoma  of  the  central
ervous  system  is  a  diagnosis  by  exclusion.  However,  it  rep-
esents  a challenge,  since  it  ﬁrst  has  to  be  suspected,  and
hen  try  to  exclude  primary  melanotic  lesions  with  higher
ncidence  and  prevalence.  The  difﬁculty  in  establishing  this
iagnosis  is  secondary  to  the  variants  of  behaviour  presented
n  imaging  studies  of  this  tumour.  In  the  case  we  presented,
n  intraventricular  meningioma  was  suspected,  and  the  signs
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bserved  in  the  magnetic  resonance  were  not  taken  into
onsideration,  in  accordance  with  the  malanotic  pattern  of
so/hyperintensity  in  T1  and  hypointensity  in  T2.
The  extremely  low  incidence  of  this  tumour  has  not
llowed  the  development  of  management  and  diagnostic
uidelines;  therefore,  the  prognosis  is  still  discouraging  in
eneral,  only  supported  by  the  fact  of  a  resection  as  exten-
ive  as  possible  of  the  lesion.  It  is  necessary  to  perform
 deep  study  of  the  genesis  of  primary  melanoma  of  the
entral  nervous  system  in  order  to  use  speciﬁc  therapeutic
pproaches  with  immunotherapy,  chemotherapy  and  radio-
herapy.  Further,  the  differential  diagnosis  between  primary
nd  metastatic  malignant  melanoma  of  the  central  nervous
ystem  continues  to  be  complex.  Hayward’s  criteria  are  used
o  perform  the  differential  diagnosis  between  these  two
iseases.28 An  extracranial  lesion  has  to  be  ruled  out  scrupu-
ously  before  making  a  diagnosis  of  primary  melanoma  of  the
entral  nervous  system.
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